

FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics

Conrado, D.J., et al.; “FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics.” 10th Clinical Trials on Alzheimer’s Disease (CTAD), Boston, MA, November 1-4, 2017, *The Journal of Prevention of Alzheimer’s Disease* 4(4): 345.